期刊
DIAGNOSTICS
卷 11, 期 8, 页码 -出版社
MDPI
DOI: 10.3390/diagnostics11081341
关键词
melanoma; biomarkers; molecular pathology; genetic mutations; prognosis
The use of biomarkers in medicine is crucial for diagnosis, prognostication, and prediction of treatment response. With advancements in understanding DNA mutational profiles, new gene targets and proteins are being identified. Currently, only a small number of available biomarkers are being utilized, but this could change with more research being published.
The use of biomarkers in medicine has become essential in clinical practice in order to help with diagnosis, prognostication and prediction of treatment response. Since Alexander Breslow's original report on melanoma and prognostic values of thickness, providing the first biomarker for melanoma, many promising new biomarkers have followed. These include serum markers, such as lactate dehydrogenase and S100 calcium-binding protein B. However, as our understanding of the DNA mutational profile progresses, new gene targets and proteins have been identified. These include point mutations, such as mutations of the BRAF gene and tumour suppressor gene tP53. At present, only a small number of the available biomarkers are being utilised, but this may soon change as more studies are published. The aim of this article is to provide a comprehensive review of melanoma biomarkers and their utility for current and, potentially, future clinical practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据